Outcomes of Degenerative Disc Disease Patients Treated With an Anterior-Only Fusion Using InQu Bone Graft (InQu)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01746212|
Recruitment Status : Unknown
Verified December 2012 by Mark Camden Whitaker, Kansas Joint and Spine Institute.
Recruitment status was: Recruiting
First Posted : December 10, 2012
Last Update Posted : December 10, 2012
The purpose of this study is to report the radiographic, clinical, and functional outcomes of a consecutive series of patients diagnosed with single or bilateral degenerative disc disease between L4 and S1, that have been treated with an anterior lumbar interbody fusion (ALIF), anterior only surgical approach, and InQu Bone Graft Extender and Substitute for bony fusion and instrumentation.
Patients that decide to undergo an Anterior Lumbar Interbody Fusion (ALIF) surgery [a surgical procedure that joins two or more lumbar vertebrae (small bones of the spine) together into one solid bony structure by approaching the spine through the abdomen (front of the body) and placing a bone graft in between the vertebral bodies where the disc usually lies], are invited to participate in an orthopaedic research study.
This study will compare patients that have been treated with an anterior lumbar interbody fusion using InQu Bone Graft Extender & Substitute to published data for a stand alone spinal fusion surgery, where InFuse bone graft is placed between the transverse processes [small bony projections off the right and left side of each bone in your spine] of the affected vertebrae.
X-rays, daily activities, and how patients are doing will be evaluated at specific time points during this study.
The hypothesis of this study is that patients diagnosed with degenerative disc disease treated with an anterior lumbar interbody fusion, anterior only surgical approach (incision through the abdomen), using InQu Bone Graft Extender and Substitute and instrumented fixation have comparable radiographic (x-rays), functional (daily activities), and clinical (how the patient is doing) outcomes when compared to published data for use of InFuse in stand-alone fusion.
|Condition or disease||Intervention/treatment|
|Degenerative Disc Disease||Procedure: One-level or two-level anterior lumbar interbody fusion Biological: InQu Bone Graft Extender and Substitute mixed with BMAC Device: Synthes Spinal Instrumentation|
This is a prospective, observational study; evaluating outcomes of patients that have elected to receive surgical intervention in order to treat degenerative disc disease. In order to be eligible for enrollment into this study, patients have already elected to be treated with an anterior lumbar interbody fusion, an anterior only approach for single or bi-level degenerative disc disease between L4 and S1 with instrumented fusion, using a combination of InQu Bone Graft Extender and Substitute, local bone, and Bone Marrow Aspirate Concentrate (BMAC) to promote bony fusion. Only after the patient and physician determine the surgical procedure, can the patient be eligible for enrollment. A consecutive series of 60 patients will be offered enrollment if all inclusion/exclusion criteria are met.
Data will be collected by chart review to include pre-operative, surgical, functional, post-operative, and radiographic imaging charted data, collected as part of the routine clinical visit, and standard of care.
Follow-up data will include newly charted clinical, functional, and radiographic imaging data, including dynamic x-rays and CT scans to be obtained prospectively at a minimum of one (1) year post-operatively. During the routine post-surgical visits, patient pain outcomes are measured using the Visual Analog Scale (VAS) for back and leg pain, function is measured by the Oswestry Disability Index (ODI) and Short Form-12 Version 2 (SF-12 Version 2 Health Survey). A physician investigator will also perform routine clinical evaluations.
The patients will undergo standard radiographic procedures to obtain x-rays (including lateral, anterior-posterior, and dynamic flexion/extension) as part of the standard of care. A CT scan will be performed for research purposes as indicated in the protocol follow-up procedure. X-rays and CT scans will be evaluated by an independent radiologist and a physician investigator to determine anterior fusion status and the status of the anterior hardware constructs.
The National Center of Innovation for Biomaterials in Orthopaedic Research and Medical Metric, Inc. will assist with imaging analysis of x-rays and CTs.
ISTO Technologies, Inc. will be providing a grant to cover costs associated with the research components of this study.
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||Outcomes of Patients With Lumbar Degenerative Disc Disease Treated Operatively With an Anterior-Only Approach Using InQu Bone Graft Extender and Substitute|
|Study Start Date :||December 2012|
|Estimated Primary Completion Date :||March 2015|
|Estimated Study Completion Date :||May 2015|
Degenerative Disc Disease
Patients diagnosed with degenerative disc disease, meeting all eligibility requirements (please refer to inclusion/exclusion criteria), will be asked to participate in this study. A one-level or two-level anterior lumbar interbody fusion surgery using InQu Bone Graft Extender and Substitute, mixed with BMAC (bone marrow aspirate concentrate) as autograft, with Synthes Spinal Instrumentation will be recommended to the patient. If patients elect to proceed with surgery using the prescribed surgical components, they will be offered enrollment into the study. If the patient opts to use a different bone graft, or other spinal instrumentation, then the patient will not meet all inclusion criteria and will not be offered the opportunity to enroll in this study.
Procedure: One-level or two-level anterior lumbar interbody fusion
Patients electing to receive a one-level or two-level, anterior approach only (incision through the front), lumbar interbody fusion in order to treat degenerative disc disease (at one or two levels in the spine), and meeting all other inclusion criteria, are eligible for enrollment into the study.
Other Name: ALIF
Biological: InQu Bone Graft Extender and Substitute mixed with BMAC
Surgeries utilizing InQu Bone Graft Extender and Substitute during the anterior lumbar interbody fusion surgical procedure will be elected for inclusion. InQu will be mixed with BMAC (bone marrow aspirate concentrate), which will be prepared using the SmartPRep2 centrifuge. Patients opting to use a grafting alternative will not meet inclusion criteria, and will not be eligible to enroll in this study.
Device: Synthes Spinal Instrumentation
Synthes Spinal Instrumentation will be used during surgery as spinal stabilization.
- Evidence of successful radiographic fusion at 1-year post-operative [ Time Frame: 12-months post-operative ]
X-rays and CTs will be analyzed for fusion based on the following criteria:
- Bridging trabecular bone connecting the two vertebral bodies either through the dowels or around the dowels as evaluated by thin-cut CT scans and radiographs;
- No angular motion of 5 degrees or more on dynamic plain radiographs;
- No sagittal translation of more than 3 mm on dynamic plain radiographs; and
- No radiolucencies that involve more than half of the interfaces between the dowels and the host vertebral end plates.
Criteria is based on the Burkus, Transfelt, et. al study titled "Clinical and Radiographic Outcomes of Anterior Lumbar Interbody Fusion Using Recombinant Human Bone Morphogenetic Protein-2."
- Improvement in Oswestry Disability Index Score (1-year) [ Time Frame: Change from baseline to 12-months post-operative ]Change in ODI and between baseline and 1-year post-operative, anticipating improvement in ODI score (i.e. from baseline to 12-months post-operative, scores should decrease).
- Improvement in Oswestry Disability Index Scores (2-years) [ Time Frame: Change from baseline to 24-month post-operative ]Change in ODI and between baseline and 2-year post-operative, anticipating improvement in ODI score (i.e. from baseline to 24-months post-operative, scores should decrease).
- Improvement in Visual Analog Scale Scores (1-year) [ Time Frame: Change from baseline to 12-months post-operative ]Change in VAS and between baseline and 1-year post-operative, anticipating improvement in VAS score (i.e. from baseline to 12-months post-operative, scores should decrease).
- Improvement in Visual Analog Scale Scores (2-years) [ Time Frame: Change from baseline to 24-months post-operative ]Change in VAS and between baseline and 2-year post-operative, anticipating improvement in VAS score (i.e. from baseline to 24-months post-operative, scores should decrease).
- Surgical Outcomes [ Time Frame: At time of surgery ]Estimated blood loss, Operative time, Hospital stay
- Radiographic Measurements at 6-months post-operative [ Time Frame: Change from baseline to 6-months post-operative ]Evaluation of Disc Height, Mean Optical Density, and Integrated Optical Density
- Radiographic Measurements at 12-months post-operative [ Time Frame: Change from baseline to 12-months post-operative ]Evaluation of Disc Height, Mean Optical Density, and Integrated Optical Density
- Radiographic Measurements at 18-months post-operative [ Time Frame: Change from baseline to 18-months post-operative ]Evaluation of Disc Height, Mean Optical Density, and Integrated Optical Density
- Radiographic Measurements at 24-months post-operative [ Time Frame: Change from baseline to 24-months post-operative ]Evaluation of Disc Height, Mean Optical Density, and Integrated Optical Density
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01746212
|Contact: Jennifer Duong||316-858-1900 ext firstname.lastname@example.org|
|United States, Kansas|
|Kansas Joint and Spine Institute||Recruiting|
|Wichita, Kansas, United States, 67226|
|Contact: Jennifer Duong, BA 316-858-1900 ext 110 email@example.com|
|Contact: Mark C. Whitaker, MD 316-858-1900 firstname.lastname@example.org|
|Principal Investigator: Mark C. Whitaker, MD|
|Sub-Investigator: John Lammli, MD|
|Sub-Investigator: Alan Moskowitz, MD|
|Sub-Investigator: Brent Adams, MD|
|Sub-Investigator: Kris Lewonowski, MD|
|Sub-Investigator: Jennifer Duong, BA|
|National Center of Innovation for Biomaterials in Orthopaedic Research||Active, not recruiting|
|Wichita, Kansas, United States, 67226|
|Principal Investigator:||Mark C Whitaker, MD||Kansas Joint and Spine Institute|